Navigation Links
CRE Statement on "Inherent Reasonableness" for Retail Pharmacy Diabetic Supplies
Date:7/24/2012

WASHINGTON, July 24, 2012 /PRNewswire/ -- The Center for Regulatory Effectiveness' Statement, delivered at today's CMS Public Meeting on:  "Inherent Reasonableness of Medicare Fee Schedule Amounts for Non-Mail Order (Retail) Diabetic Testing Supplies," is attached in pdf here and reprinted below.  The Federal Register notice for the meeting is attached here.  Comments are due to CMS by July 30th although the date may be extended.

Statement of the:

Center for Regulatory Effectiveness

before the Centers for Medicare and Medicaid Services

Public Meeting Regarding Inherent Reasonableness of Medicare Fee Schedule Amounts for Non-Mail Order (Retail) Diabetic Testing Supplies

July 23, 2012

Introduction

I'm Bruce Levinson, Senior Vice President, Regulatory Intervention at the Center for Regulatory Effectiveness. We're a regulatory watchdog focused on ensuring agency compliance with the "good government" laws that regulate the regulators.

I would like to start by thanking CMS for holding this public meeting. This meeting is an important example of outreach activities that President Obama called for in his landmark Open Government Memorandum which directed agencies to be Transparent, Participatory and Collaborative.

CMS Does Not Have "Valid and Reliable Data" for Use in Setting Diabetic Supply Prices

CMS' Federal Register notice for this meeting stated that, according to their own rules, they must "use valid and reliable data" in determining whether a payment amount is "grossly excessive or deficient."

The competitive bidding data from the Round 1 Rebid, however, is emphatically NOT valid and reliable.  That's not CRE's view, that's the considered view of hundreds of economists and auction experts from virtually every major university.

A letter to the President signed by over 240 academicians, including several Nobel laureates, stated the following:

  • CMS competitive bidding program violates all of the principles [of President Obama's Executive Order on regulation], especially the principles of transparency and of basing regulations on the best available science. Indeed, the current program is the antithesis of science and contradicts all that is known about proper market design.

Specific problems with CMS' bidding design cited by the economists include:

  • The use of non-binding bids together with setting the price equal to the median of the winning bids provides a strong incentive for low-ball bids—submitting bids dramatically below actual cost.
  • The problems with the CMS auction grow worse upon closer inspection. The complete lack of transparency is inappropriate for a government auction.

An article published in the Quarterly Journal of Economics by researchers at the California Institute of Technology concluded:

  • The CMS auction fails to generate competitive prices of goods and fails to satisfy demand.
  • the CMS auction performs poorly as a procurement auction.
  • RESULT 5.  Prices generated in the CMS auction do not approximate the competitive price. They are significantly and consistently lower than the competitive price.
  • The challenge, for those who are unconvinced by the evidence that the CMS auction will perform poorly, is to explain why the principles seen operating so clearly in the laboratory environment will not operate when the auction is deployed in the field.

The study was financed by the Gordon and Betty Moore Foundation with additional support from a National Science Foundation grant.

The Data Quality Act and CMS' Regulatory Plans

The results from the Round 1 Rebid not only don't comply with CMS requirements for "inherent reasonableness," they also don't comply with the quality standards established by Congress and implemented by the White House Office of Management and Budget through the Data Quality Act.

The Data Quality Act provides affected parties the right to "seek and obtain" correction of information not meeting quality standards.

If anyone here would like to know more about the DQA and participating in exercising their right to "seek and obtain" correction of the Round 1 Rebid results, please see me, I'll be here through the end of the meeting.


'/>"/>
SOURCE Center for Regulatory Effectiveness
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
2. Lilly Statement on Affordable Care Act Ruling by Supreme Court
3. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in the U.S. Senate
4. Lilly Statement on PDUFA Vote by Senate
5. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in House of Representatives
6. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
7. American Society of Hematology Statement on House Passage of Prescription Drug User Fee Act (PDUFA)
8. American Society of Hematology Statement on Senate Passage of Prescription Drug User Fee Act (PDUFA)
9. Icahn Issues Statement Regarding Amylin Pharmaceuticals
10. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
11. La Jolla Pharmaceutical Company Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... NEW YORK , January 23, 2017 ... assessment: Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX ), Sophiris ... (NASDAQ: MNTA ), and Agile Therapeutics Inc. (NASDAQ: ... Healthcare sector which turned somewhat lower in late trade on ... Care Index dropping about 0.3%, while shares of health care ...
(Date:1/23/2017)... , January 23, 2017 The global  anxiety disorders and ... by 2025. The rising incidence of depression worldwide is anticipated to drive the ... resulted in the declining demand for antidepressants in the recent years. ... ... Grand View Research Logo ...
(Date:1/23/2017)... and PALMA, Spain ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused ... the first patient has been enrolled in the ... candidate, SNF472, for the treatment of cardiovascular calcification ... Most ESRD patients, in the last ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... 2017 , ... Moisture measurement is a necessary process step ... to success. Selecting an inappropriate measurement method can cause costly errors, and poor ... equipment. Rare or expensive substances are wasted and production may even be stopped ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... Foundation (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), the ... (APSF), the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... (SNP) has launched online education programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources ... benefits of a seafood-rich diet. These resources have been developed for use ...
(Date:1/22/2017)... ... January 22, 2017 , ... Phytocéane invites clients to ... the rest of the world with ZANZIBAR MILKY CREAM. Inspired by the beauty of ... like Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, velvety body ...
(Date:1/21/2017)... , ... January 21, 2017 , ... Caronlab Australia, an ... the January ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding ... the quality of its beauty and wellness products. At this trade show, the company ...
Breaking Medicine News(10 mins):